Caicun Zhou

Professor and lead investigator, Shanghai East Hospital, Tongji University

Appears in 1 story

Stories

Antibody-drug conjugate combination outperforms chemo-immunotherapy in PD-L1-negative lung cancer

Presented OptiTROP-Lung06 results at ESMO 2026 (LBA66)

A trial pairing an antibody-drug conjugate with the immunotherapy pembrolizumab cut the risk of disease progression or death by 51% in patients with PD-L1-negative advanced lung cancer. The OptiTROP-Lung06 results were presented at the 2026 European Society for Medical Oncology (ESMO) congress in Madrid and published the same day in the New England Journal of Medicine.

Updated 1 hour ago